| Q36391900 | A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication |
| Q39037052 | Antibiotic-dependent expression of early transcription factor subunits leads to stringent control of vaccinia virus replication |
| Q36103012 | B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals |
| Q56564084 | Construction of an attenuated Tian Tan vaccinia virus strain by deletion of TA35R and TJ2R genes |
| Q28297101 | Edward Jenner's Inquiry; a bicentenary analysis |
| Q58707232 | Efficacy and Safety of BCG Vaccine for Control of Tuberculosis in Domestic Livestock and Wildlife |
| Q33475308 | Emerging diseases, zoonoses and vaccines to control them |
| Q35954584 | Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres |
| Q33589223 | Epidemiology and control of fox rabies in Europe |
| Q38728732 | Future Prospects for the Development of Cost-Effective Adenovirus Vaccines |
| Q45324442 | Generation of an Attenuated Tiantan Vaccinia Virus Strain by Deletion of Multiple Genes |
| Q37153663 | Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines. |
| Q37617613 | IL-18 expression results in a recombinant vaccinia virus that is highly attenuated and immunogenic |
| Q40045372 | Immunogenicity of ORFV-based vectors expressing the rabies virus glycoprotein in livestock species |
| Q45732361 | Immunogenicity of a recombinant lumpy skin disease virus (neethling vaccine strain) expressing the rabies virus glycoprotein in cattle |
| Q34978326 | Immunoprophylaxis against important virus disease of horses, farm animals and birds |
| Q30339052 | Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. |
| Q34106038 | Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins |
| Q38830323 | Multivalent and Multipathogen Viral Vector Vaccines |
| Q41006477 | Non-replicating expression vectors: applications in vaccine development and gene therapy |
| Q38156497 | Overview of vaccination trials for control of tuberculosis in cattle, wildlife and humans |
| Q35159089 | Poxviruses as vaccine vectors |
| Q34341579 | Present and future of veterinary viral vaccinology: a review |
| Q40117821 | Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology |
| Q34422345 | Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs |
| Q38735052 | Rabies vaccine development by expression of recombinant viral glycoprotein |
| Q36066267 | Recombinant DNA technology for producing new rinderpest virus vaccines |
| Q34303979 | Recombinant vaccine technology in veterinary medicine. |
| Q41587132 | Recombinant viruses as vaccines and immunological tools |
| Q37337252 | Review of companion animal viral diseases and immunoprophylaxis |
| Q34612390 | Smallpox vaccination techniques; from knives and forks to needles and pins. |
| Q24650479 | The Jenner bicentenary; still uses for smallpox vaccine |
| Q26995905 | The evolution of poxvirus vaccines |
| Q36657196 | The potential of oral vaccines for disease control in wildlife species |
| Q53621283 | Two hundred years of vaccination. |
| Q73882460 | Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection |
| Q73687847 | Vaccine immunity |
| Q37343595 | Vaccinia virus vaccines: past, present and future |
| Q33834391 | Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity |
| Q35571248 | Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. |
| Q91911915 | Veterinary Vaccines and Their Importance to Animal Health and Public Health |
| Q37099833 | Veterinary vaccine development from an industrial perspective |